Unknown

Dataset Information

0

COVID-19 and COPD


ABSTRACT: As of 11 July, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic has infected over 12.7 million people around the world and caused more than 560,000 deaths [1]. Given the devastating impact that COVID-19 can have on the lung, it is natural to fear for patients with underlying COPD. Estimating their excess risk for contracting COVID-19 and, in particular, its more severe respiratory manifestations has been a challenging exercise in this pandemic for various reasons. First, the reporting on cases has concentrated on hospitalised and intensive care unit (ICU) patients, rather than on mild, outpatient cases. This is in part also due to the variability in testing strategies across the world, where some nations with stricter testing requirements and scarce testing resources have focused on testing only those requiring hospitalisation. COPD patients have increased risk of severe pneumonia and poor outcomes when they develop COVID-19. This may be related to poor underlying lung reserves or increased expression of ACE-2 receptor in small airways.https://bit.ly/37dSB8l

SUBMITTER: Leung J 

PROVIDER: S-EPMC7424116 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Similar Datasets

| S-BSST563 | biostudies-other
| S-BSST416 | biostudies-other
| S-EPMC10253799 | biostudies-literature
| PRJEB42396 | ENA
| PRJEB62576 | ENA
2024-09-26 | E-MTAB-13593 | biostudies-arrayexpress
| S-SCDT-EMM-2021-15227 | biostudies-other
| S-SCDT-EMM-2020-13038 | biostudies-other
| S-BSST1269 | biostudies-other
2023-01-17 | GSE211972 | GEO